Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203749 | 0.82 | TSHR (0.45) | PKM | |
| SCHEMBL19567145 | 0.77 | CTSL (0.55) | CTSSCTSLCTSBAKT1 | |
| SCHEMBL20187564 | 0.76 | AKT1 (0.60) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL782348 | 0.75 | AKT1 (0.55) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL6988751 | 0.75 | ALOX5 (0.49) | SMN1; SMN2PKM | |
| SCHEMBL17384424 | 0.74 | CTSL (0.50) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL6993125 | 0.74 | TSHR (0.50) | PKM | |
| SCHEMBL19567152 | 0.73 | CTSL (0.49) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL4743853 | 0.72 | KMT2A (0.55) | CTSSCTSLCTSBCTSK | |
| SCHEMBL19567146 | 0.72 | ALDH1A1 (0.53) | CTSSCTSLCTSBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656910-B2 | Serine protease inhibitors | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-6656911-B2 | Oxadiazole ring structure peptoids which are useful as inhibitors of serine proteases | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | CORTECH, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6608175-B2 | Oxadiazole, thiadiazoles or triazole metal derivatives reacted with an amine containing aldehyde, deprotecting, coupling with an acid and oxidizing to create substituted oxadiazole, thiadiazole or triazole peptoids | CORTECH, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030060418-A1 | Serine protease inhibitors | CORTECH, INC. | 2003-03-27 | — | — | US | disclosed |
| US-20020119998-A1 | Serine protease inhibitors | CORTECH, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020119985-A1 | Serine protease inhibitors | CORTECH, INC. | 2002-08-29 | — | — | US | disclosed |
| US-6150334-A | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE STRUCTURES WHICH ARE USEFUL AS INHIBITORS OF SERINE PROTEASES, INCLUDING HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. | 2000-11-21 | — | — | US | disclosed |
| CN-1247542-A | Serine protease inhibitors | CORTECH INC (US) | 2000-03-15 | — | — | CN | disclosed |
| US-6015791-A | Serine protease inhibitors-cycloheptane derivatives | CORTECH INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-6001811-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSIS, MULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5998379-A | USEFUL AS INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HUMAN NEUTROPHIL ELASTASE, TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, AND MYOCARDIAL ISCHEMIA-REPERFUSION INJURY | CORTECH INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0954526-A2 | SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5891852-A | Serine protease inhibitors-cycloheptane derivatives | CORTECH, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5869455-A | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS WHICH ARE USEFUL AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5861380-A | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIARTHRITIC,-INFLAMMATORY,-ISCHEMIC,-TUMOR AND -CARCINOGENIC AGENTS AND OTHER HNE-MEDIATED CONDITIONS | CORTECH, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5807829-A | RESPIRATORY SYSTEM DISORDERS; SESPIC SHOCK; ORGAN FAILURE | CORTECH, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5801148-A | Serine protease inhibitors-proline analogs | CORTECH, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1998024806-A2 | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119985-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | CTSS 106/4885CTSL 130/4885CTSB 353/4885 |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | TNNI3, PEPD, STK35 | CTSS 535/4885CTSL 782/4885CTSB 1831/4885 |
| US-20030060418-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | CTSS 106/4885CTSL 130/4885CTSB 353/4885 |
| US-20020119998-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | CTSS 106/4885CTSL 130/4885CTSB 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.